Date change for Genovis AB January-September 2013 interim report

The Board of Directors of Genovis AB (publ) has decided to schedule the January
– September 2013 interim report earlier. The report was to have been published
on November 28 and the new publication date is November 18, 2013.
CEO Sarah Fredriksson will comment on the interim report at Financial Meetings
Øresund’s morning meeting on November 18. Redeye analyst Klas Palin will ask
questions immediately after the report is presented. The presentation will take
place from 8 a.m. to 10 a.m. at Årstiderna By The Sea, Dockgatan 1, Malmö.
Breakfast is served from 7:30. The morning meeting is free, but participants
must register by November 13: rapport@financialmeetings.se

The presentation will be direct broadcast on the following technical platforms:

www.genovis.com/investors-swedish

www.financialmeetings.se

www.redeye.se

ABOUT FINANCIAL MEETINGS ØRESUND

Financial Meetings Øresund was founded in 2013 and is a brand new financial
meeting place, an arena, with interesting financial arrangements for and with
Öresund companies, market analysts, investors and media.
For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46
(0)46 -101235 sarah.fredriksson@genovis.com
ABOUT GENOVIS

Genovis’ business concept is to develop, produce and market innovative
technologies that facilitate and enable development of new treatment methods and
diagnostics for customers in the medical device and pharmaceutical industries.
The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis
develops and sells unique enzymes (protein engineering portfolio) in innovative
product formats that facilitate development and quality control of and
biological drugs. GeccoDots uses nanotechnology to produce a new type of
contrast agent that is used in medical imaging.

Genovis shares are listed on NASDAQ OMX First North, and Thenberg Fondkommission
is Certified Adviser for the Company, t: 46 (0)31-745 50 00